Stockscreener 앱 받기
44.69
1.56%
-0.71
시간 외 거래:
44.91
0.22
+0.49%
전일 마감가:
$45.40
열려 있는:
$45.4
하루 거래량:
3.53M
Relative Volume:
1.21
시가총액:
$12.19B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
25.25
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
+20.85%
1개월 성능:
+23.49%
6개월 성능:
+29.88%
1년 성능:
+113.73%
1일 변동 폭
$44.49
$46.22
1주일 범위
$36.24
$48.85
52주 변동 폭
$20.14
$48.85
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.69 | 10.08B | 2.17B | 521.27M | 633.79M | 1.77 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio? - Benzinga
Exelixis raises 2025 revenue guidance by $100M amid strong CABOMETYX market share gains and new NET approval - MSN
Exelixis director George Poste sells $948,957 in stock - Investing.com
Exelixis director George Poste sells $948,957 in stock By Investing.com - Investing.com UK
Exelixis Stock Price, Quotes and Forecasts - Benzinga
Exelixis Q1 2025 Earnings Call Highlights Growth - TipRanks
Guggenheim Raises Price Target for Exelixis (EXEL) Amid Strong R - GuruFocus
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line - MSN
Demystifying Exelixis: Insights From 8 Analyst Reviews - Benzinga
Exelixis (EXEL) Target Price Raised by Citigroup Analyst | EXEL Stock News - GuruFocus
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Citi Elevates Price Target for Exelixis (EXEL) to $56 Amid Stron - GuruFocus
Exelixis (EXEL) Receives Increased Price Target, Maintains Stron - GuruFocus
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday - MSN
10 Firms Blowing Up by Double Digits Today - Insider Monkey
Exelixis stock target raised to $47 by JMP on strong sales - Investing.com Australia
Exelixis (EXEL) Boosts 2025 Revenue Forecast After Strong Q1 | E - GuruFocus
Exelixis (EXEL) Price Target Raised by Morgan Stanley | EXEL Sto - GuruFocus
Exelixis (EXEL) Maintains Outperform Rating with $40 Price Targe - GuruFocus
U.S. Markets Finished Mixed Wednesday As Exelixis Led, Ubiquiti Lagged - Barron's
Transcript : Exelixis, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
Exelixis Is Up Today, Analyst Weighs InExelixis (NASDAQ:EXEL) - Benzinga
Stifel raises Exelixis stock price target to $38 on robust sales - Investing.com Nigeria
Exelixis: A Notable Quarter (NASDAQ:EXEL) - Seeking Alpha
Exelixis Q1 2025 slides: Revenue up 31%, raises FY guidance on CABOMETYX strength By Investing.com - Investing.com South Africa
eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal - Yahoo Finance
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday - Investing.com Australia
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com South Africa
Exelixis (EXEL) Boosts 2025 Revenue Guidance After Strong Q1 Per - GuruFocus
Why Exelixis (EXEL) Shares Are Surging Today - GuruFocus
Why Exelixis Stock Is Skyrocketing Today - Yahoo Finance
EXEL Stock Target Raised to $44 by TD Cowen Analyst | EXEL Stock News - GuruFocus
Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance - Benzinga
EXEL Stock: Market Uncertainty Highlights Strong Fundamentals | - GuruFocus
Exelixis Announces First Quarter 2025 Financial Results and Prov - GuruFocus
Exelixis, Inc. (NASDAQ:EXEL) Q1 2025 Earnings Call Transcript - Insider Monkey
Exelixis price target raised to $47 from $40 at Morgan Stanley - TipRanks
Exelixis (EXEL) Receives Price Target Boost Following Strong Sal - GuruFocus
Morgan Stanley Adjusts Price Target on Exelixis to $47 From $40, Maintains Overweight Rating - marketscreener.com
Exelixis Hold Rating: Strong Performance and Promising Pipeline Balanced by Fair Valuation - TipRanks
Exelixis (EXEL) Receives Price Target Boost to $46 | EXEL Stock News - GuruFocus
Exelixis price target raised to $46 from $41 at Citizens JMP - TipRanks
Exelixis Q1 2025 Earnings Call Transcript - MarketBeat
Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update - BioSpace
Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors - BioSpace
Exelixis Q1 2025 slides: Revenue up 31%, raises FY guidance on CABOMETYX strength - Investing.com Nigeria
Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply - Yahoo Finance
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
자본화:
|
볼륨(24시간):